These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33410895)

  • 1. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
    Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
    Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
    Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
    J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
    [No Abstract]   [Full Text] [Related]  

  • 3. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
    Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
    Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
    Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
    [No Abstract]   [Full Text] [Related]  

  • 5. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
    Álvarez Román MT; Fernández Bello I; Arias-Salgado EG; de Paz R; Jiménez Yuste V; Martín Salces M; Butta NV
    Br J Clin Pharmacol; 2014 Sep; 78(3):674-6. PubMed ID: 24602175
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
    Ruggeri M
    Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 9. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
    Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
    Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 11. What is publication? The case of eltrombopag.
    Benham L; Guo L; Turner R
    Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
    [No Abstract]   [Full Text] [Related]  

  • 12. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract]   [Full Text] [Related]  

  • 13. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
    Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune thrombocytopenia during childhood: new approaches to classification and management.
    Buchanan GR
    J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
    [No Abstract]   [Full Text] [Related]  

  • 15. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
    Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ; Swart RM; te Boekhorst PA
    N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
    Sartori R; Candiotto L; Ruggeri M; Tagariello G
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s151-2. PubMed ID: 24120607
    [No Abstract]   [Full Text] [Related]  

  • 19. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
    Francesco R
    Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
    [No Abstract]   [Full Text] [Related]  

  • 20. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.